Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

hC Bioscience and 4SR Biosciences Join Forces to Expand Platform Development of tRNA-Based Therapies

By: Newsfile

Cambridge, Massachusetts--(Newsfile Corp. - January 17, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics. Their technologies will be used to discover and optimize tRNAs capable of overcoming genetic errors to treat genetic disease and cancer. As part of the acquisition, Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology and a pioneer in tRNA technology and biology, will join hC Bioscience as a scientific advisor and member of its Scientific Advisory Board, Christopher Katanski, Ph.D., will join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D., will join as Associate Director of Discovery Platform.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • hC Bioscience and 4SR Biosciences consolidate complementary technologies, IP and know-how related to the design and development of tRNA-based therapies.
  • Combined organization will apply multiple tRNA-based therapeutic strategies to target genetic disease and cancer.
  • Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Chicago to join hC Bioscience as a scientific advisor and member of the SAB; Christopher Katanski, Ph.D. to join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D. to join as Associate Director of Discovery Platform.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/151542_figure1_550.jpg

Click image above to view full announcement.


About hC Bioscience, Inc.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. The Company has raised $40 million to date and its investors include ARCH Venture Partners, Takeda Ventures, 8VC, Taiho Ventures and Panacea Venture.

Contacts:

Savannah Beaver
(617) 804-0366
savannah@reportablenews.com

Source: hC Bioscience

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/151542

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.